非筋肉浸潤性膀胱がんの世界市場レポート 2025年

非筋肉浸潤性膀胱がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で46億1,000万米ドルに成長します。予測期間における成長の原動力は、標的療法の採用増加、個別化医療への注目の高まり、腫瘍学研究への投資拡大、低侵襲手技への需要の高まり、慢性膀胱疾患の罹患率上昇にあると見られています。予測される主な動向には、技術の進歩、精密医療の開発、人工知能の統合、遠隔医療サービスの拡大、デジタルヘルスツールの採用などがあります。

低侵襲手術の需要が非筋肉浸潤性膀胱がん市場の成長を牽引すると予測されます。低侵襲手術とは、小さな切開創と特殊な器具を使用する手術法で、従来の開腹手術に比べて組織損傷が少なく、痛みも軽減され、回復時間も短く、傷跡も最小限に抑えられます。回復期間の短縮、患者の転帰の改善、高齢化人口の増加などの要因により、低侵襲技術が重視され、患者の安全性、満足度、ヘルスケア効率が向上しています。非筋肉浸潤性膀胱がんは、経尿道的切除術や膀胱内治療などの局所治療を通じて、これらの手技を促進し、大規模な外科的介入なしに腫瘍を治療します。例えば、2023年8月にThe Aesthetic Societyは、アメリカ人が美容整形に118億米ドル以上を費やしたことを報告し、これは前年比2％増を反映しています。その結果、低侵襲処置に対する需要の増加が非筋肉浸潤性膀胱がん市場を押し上げています。

個別化医療への注目は、非筋肉浸潤性膀胱がん市場の成長をさらに促進すると予想されます。個別化医療は、より効果的な結果を得るために、個人の遺伝子プロファイル、ライフスタイル、環境に合わせた治療を行うものです。このアプローチは、ゲノム研究の進歩、診断ツールの改善、標的治療に対する需要の高まりによって勢いを増しています。非筋肉浸潤性膀胱がんは、特定の腫瘍の特徴、遺伝子マーカー、患者プロファイルに基づいてカスタマイズされた治療計画を可能にすることで、個別化医療に合致しています。例えば、個別化医療連合（Personalized Medicine Coalition）は2024年2月、FDAが希少疾患に対する新規の個別化治療を2022年の6件に対し、2023年には16件承認したと報告しています。このような個別化アプローチへの注目は、市場の成長に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界非筋肉浸潤性膀胱がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の非筋肉浸潤性膀胱がん市場：成長率分析
• 世界の非筋肉浸潤性膀胱がん市場の実績：規模と成長, 2019-2024
• 世界の非筋肉浸潤性膀胱がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界非筋肉浸潤性膀胱がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非筋肉浸潤性膀胱がん市場：ステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮内がん（CIS）
• T1ステージ
• タステージ
• 世界の非筋肉浸潤性膀胱がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 化学療法
• 手術
• 膀胱内療法
• その他の治療法
• 世界の非筋肉浸潤性膀胱がん市場腫瘍による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低悪性度腫瘍
• 高悪性度腫瘍
• 世界の非筋肉浸潤性膀胱がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の非筋肉浸潤性膀胱がん市場上皮内がん（CIS）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高品位CIS
• 低悪性度CIS
• 世界の非筋肉浸潤性膀胱がん市場、T1ステージのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• T1a期（表在性腫瘍）
• T1b期（固有層への浸潤）
• 世界の非筋肉浸潤性膀胱がん市場、Taステージのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低グレードTaステージ
• 高級タステージ

第7章 地域別・国別分析

• 世界の非筋肉浸潤性膀胱がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非筋肉浸潤性膀胱がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非筋肉浸潤性膀胱がん市場：競合情勢
• 非筋肉浸潤性膀胱がん市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Janssen Research & Development LLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma US Inc.
• Ferring Pharmaceuticals
• EMD Serono Inc.
• Fidia Farmaceutici SpA
• Genentech Inc.
• Aura Biosciences Inc.
• UroGen Pharma Ltd.
• Asieris Pharmaceuticals
• Protara Therapeutics Inc.
• Hamlet Pharma AB
• Istari Oncology Inc.
• Heat Biologics Inc.
• Telormedix SA
• Viventia Bio Inc.
• Theralase Technologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非筋肉浸潤性膀胱がん市場2029：新たな機会を提供する国
• 非筋肉浸潤性膀胱がん市場2029：新たな機会を提供するセグメント
• 非筋肉浸潤性膀胱がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer localized to the inner layers of the bladder wall, without infiltration into the muscle layer. It is generally diagnosed at an early stage and can often be effectively managed through treatments such as transurethral resection, intravesical therapy, or close monitoring.

The main stages of NMIBC include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ refers to abnormal cells confined to the bladder lining without spreading to deeper tissues. Treatment options for NMIBC include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, with tumors categorized as low-grade or high-grade. The end users for NMIBC treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The non-muscle invasive bladder cancer market research report is one of a series of new reports from The Business Research Company that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historical period can be attributed to an aging population, increased healthcare spending, improved healthcare infrastructure, the expansion of telemedicine, and a rise in smoking rates.

The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Projected growth in the forecast period is expected to be driven by the rising adoption of targeted therapies, an increasing focus on personalized medicine, growing investments in oncology research, heightened demand for minimally invasive procedures, and a rising incidence of chronic bladder conditions. Key trends anticipated include advancements in technology, the development of precision medicine, the integration of artificial intelligence, the expansion of telemedicine services, and the adoption of digital health tools.

The demand for minimally invasive procedures is anticipated to drive the growth of the non-muscle invasive bladder cancer market. These procedures involve surgical techniques utilizing small incisions and specialized instruments, resulting in less tissue damage, reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. Factors such as shorter recovery periods, improved patient outcomes, and a growing aging population contribute to the rising emphasis on minimally invasive techniques, enhancing patient safety, satisfaction, and healthcare efficiency. Non-muscle invasive bladder cancer facilitates these procedures through localized treatments such as transurethral resection and intravesical therapy, which target tumors without extensive surgical intervention. For example, in August 2023, The Aesthetic Society reported that Americans spent over $11.8 billion on aesthetic procedures, reflecting a 2% increase from the previous year. Consequently, the increasing demand for minimally invasive procedures is boosting the non-muscle invasive bladder cancer market.

The focus on personalized medicine is expected to further fuel the growth of the non-muscle invasive bladder cancer market. Personalized medicine tailors medical treatments to an individual's genetic profile, lifestyle, and environment to achieve more effective outcomes. This approach is gaining momentum due to advancements in genomic research, improved diagnostic tools, and a rising demand for targeted treatments. Non-muscle invasive bladder cancer aligns with personalized medicine by enabling customized treatment plans based on specific tumor characteristics, genetic markers, and patient profiles. For instance, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six approvals in 2022. This focus on personalized approaches is significantly contributing to the market's growth.

Key players in the non-muscle invasive bladder cancer market are advancing immunotherapy to enhance treatment options and patient outcomes. Immunotherapy utilizes the body's immune system to detect and combat cancer by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval, based on promising clinical trial results, highlights ANKTIVA's effectiveness when combined with Bacillus Calmette-Guerin (BCG), offering a viable option for patients unresponsive to standard BCG therapy. ANKTIVA, an innovative IL-15 agonist immunotherapy, works by stimulating natural killer (NK) cells and CD8+ killer T cells, enhancing the immune system's ability to target and destroy cancer cells.

Major players in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.

North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-muscle invasive bladder cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Muscle Invasive Bladder Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-muscle invasive bladder cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-muscle invasive bladder cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-muscle invasive bladder cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Stage: Carcinoma In Situ (CIS); T1 Stage; Ta Stage
• 2) By Treatment: Immunotherapy; Chemotherapy; Surgery; Intravesical Therapy; Others Treatments
• 3) By Tumor: Low-Grade Tumours; High-Grade Tumours
• 4) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Carcinoma In Situ (CIS): High-Grade CIS; Low-Grade CIS
• 2) By T1 Stage: T1a Stage (Superficial Tumors); T1b Stage (Invasive Into Lamina Propria)
• 3) By Ta Stage: Low-Grade Ta Stage; High-Grade Ta Stage
• Companies Mentioned:Johnson & Johnson; Janssen Research & Development LLC; Merck & Co. Inc.; AstraZeneca plc; Moderna Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Muscle Invasive Bladder Cancer Market Characteristics

3. Non-Muscle Invasive Bladder Cancer Market Trends And Strategies

4. Non-Muscle Invasive Bladder Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Muscle Invasive Bladder Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Muscle Invasive Bladder Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Muscle Invasive Bladder Cancer Market Growth Rate Analysis
• 5.4. Global Non-Muscle Invasive Bladder Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Muscle Invasive Bladder Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Muscle Invasive Bladder Cancer Total Addressable Market (TAM)

6. Non-Muscle Invasive Bladder Cancer Market Segmentation

• 6.1. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carcinoma In Situ (CIS)
• T1 Stage
• Ta Stage
• 6.2. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Chemotherapy
• Surgery
• Intravesical Therapy
• Other Treatments
• 6.3. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Grade Tumours
• High-Grade Tumours
• 6.4. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Carcinoma In Situ (CIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Grade CIS
• Low-Grade CIS
• 6.6. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of T1 Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• T1a Stage (Superficial Tumors)
• T1b Stage (Invasive Into Lamina Propria)
• 6.7. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Ta Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Grade Ta Stage
• High-Grade Ta Stage

7. Non-Muscle Invasive Bladder Cancer Market Regional And Country Analysis

• 7.1. Global Non-Muscle Invasive Bladder Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Muscle Invasive Bladder Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market

• 8.1. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Muscle Invasive Bladder Cancer Market

• 9.1. China Non-Muscle Invasive Bladder Cancer Market Overview
• 9.2. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Muscle Invasive Bladder Cancer Market

• 10.1. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Muscle Invasive Bladder Cancer Market

• 11.1. Japan Non-Muscle Invasive Bladder Cancer Market Overview
• 11.2. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Muscle Invasive Bladder Cancer Market

• 12.1. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Muscle Invasive Bladder Cancer Market

• 13.1. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Muscle Invasive Bladder Cancer Market

• 14.1. South Korea Non-Muscle Invasive Bladder Cancer Market Overview
• 14.2. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Muscle Invasive Bladder Cancer Market

• 15.1. Western Europe Non-Muscle Invasive Bladder Cancer Market Overview
• 15.2. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Muscle Invasive Bladder Cancer Market

• 16.1. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Muscle Invasive Bladder Cancer Market

• 17.1. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Muscle Invasive Bladder Cancer Market

• 18.1. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Muscle Invasive Bladder Cancer Market

• 19.1. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Muscle Invasive Bladder Cancer Market

• 20.1. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Muscle Invasive Bladder Cancer Market

• 21.1. Eastern Europe Non-Muscle Invasive Bladder Cancer Market Overview
• 21.2. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Muscle Invasive Bladder Cancer Market

• 22.1. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Muscle Invasive Bladder Cancer Market

• 23.1. North America Non-Muscle Invasive Bladder Cancer Market Overview
• 23.2. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Muscle Invasive Bladder Cancer Market

• 24.1. USA Non-Muscle Invasive Bladder Cancer Market Overview
• 24.2. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Muscle Invasive Bladder Cancer Market

• 25.1. Canada Non-Muscle Invasive Bladder Cancer Market Overview
• 25.2. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Muscle Invasive Bladder Cancer Market

• 26.1. South America Non-Muscle Invasive Bladder Cancer Market Overview
• 26.2. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Muscle Invasive Bladder Cancer Market

• 27.1. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Muscle Invasive Bladder Cancer Market

• 28.1. Middle East Non-Muscle Invasive Bladder Cancer Market Overview
• 28.2. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Muscle Invasive Bladder Cancer Market

• 29.1. Africa Non-Muscle Invasive Bladder Cancer Market Overview
• 29.2. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape And Company Profiles

• 30.1. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape
• 30.2. Non-Muscle Invasive Bladder Cancer Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Janssen Research & Development LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Muscle Invasive Bladder Cancer Market Other Major And Innovative Companies

• 31.1. Astellas Pharma US Inc.
• 31.2. Ferring Pharmaceuticals
• 31.3. EMD Serono Inc.
• 31.4. Fidia Farmaceutici SpA
• 31.5. Genentech Inc.
• 31.6. Aura Biosciences Inc.
• 31.7. UroGen Pharma Ltd.
• 31.8. Asieris Pharmaceuticals
• 31.9. Protara Therapeutics Inc.
• 31.10. Hamlet Pharma AB
• 31.11. Istari Oncology Inc.
• 31.12. Heat Biologics Inc.
• 31.13. Telormedix SA
• 31.14. Viventia Bio Inc.
• 31.15. Theralase Technologies Inc.

32. Global Non-Muscle Invasive Bladder Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Muscle Invasive Bladder Cancer Market

34. Recent Developments In The Non-Muscle Invasive Bladder Cancer Market

35. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Non-Muscle Invasive Bladder Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Muscle Invasive Bladder Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Muscle Invasive Bladder Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer